VABOMERE

Indicated For

complicated urinary tract infections (cUTI) including pyelonephritis

About This Medication

# Melinta Therapeutics Patient Assistance Program Guide: How to Get VABOMERE® (meropenem and vaborbactam) at Low or No Cost VABOMERE® (meropenem and vaborbactam) is a critical antibiotic combination used to treat serious bacterial infections, and Melinta Therapeutics offers patient assistance to help eligible individuals access it when cost is a barrier. This guide explains eligibility, application steps, and support options in simple terms. ## About VABOMERE® (meropenem and vaborbactam) **VABOMERE®** is an intravenous (IV) medication approved for adults 18 years and older with **complicated urinary tract infections (cUTIs)**, including pyelonephritis, caused by specific susceptible bacteria like *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter cloacae* species complex[1][4][5]. It combines **meropenem**, a carbapenem antibiotic, with **vaborbactam**, a beta-lactamase inhibitor designed to combat resistant gram-negative bacteria, including those producing Klebsiella pneumoniae carbapenemase (KPC)[5]. The standard dose is 4 grams (2 grams meropenem + 2 grams vaborbactam) given every 8 hours via IV infusion over 3 hours, for up to 14 days in patients with normal kidney function (eGFR ≥50 mL/min/1.73m²). Dosage adjustments are needed for renal impairment[9]. Common side effects include **headache**, **phlebitis/infusion site reactions**, and **diarrhea** (≥3% of patients). Serious risks involve seizures, especially in those prone to convulsions, and thrombocytopenia in renal impairment patients—alert your doctor if you experience delirium, headaches, or paresthesias[5][9]. Always follow your healthcare provider's instructions and report side effects to Melinta at 1-844-633-6568 or FDA at 1-800-FDA-1088[9]. VABOMERE® is typically hospital-administered due to IV delivery, but assistance programs can help with outpatient access if prescribed[10]. Melinta Therapeutics, LLC, the manufacturer, prioritizes patient access, as seen in their support for other drugs like Kimyrsa®[2][3][7]. ## Who Qualifies for Melinta Therapeutics Patient Assistance? Melinta Therapeutics, Inc. runs a **Patient Assistance Program (PAP)** offering free medication to those who cannot afford it[3]. While specific VABOMERE® details are limited publicly, general PAP criteria from Melinta and industry standards apply: - U.S. residents (often citizens or legal residents). - Uninsured or underinsured patients. - Household income typically at or below **400-500% of the Federal Poverty Level (FPL)**, though exact thresholds vary—contact Melinta for current limits[3]. - Prescription from a licensed U.S. healthcare provider. - Meet medical necessity (e.g., confirmed susceptible infection). Patients with Medicare, Medicaid, or certain commercial insurance may have restrictions; government insurance often disqualifies[3]. Melinta's programs for similar drugs like Kimyrsa® and Orbactiv® suggest tailored support[3][7]. ## Income Eligibility Breakdown Exact VABOMERE® income limits aren't publicly detailed, but Melinta PAPs follow common pharmaceutical guidelines. Here's a general table based on 2026 FPL estimates (adjust for actuals via program): | Household Size | 400% FPL (Approx. Annual Income) | 500% FPL (Approx. Annual Income) | |----------------|---------------------------------|---------------------------------| | 1 (Individual) | $60,000 | $75,000 | | 2 (Couple) | $81,000 | $101,000 | | 3 | $102,000 | $127,000 | | 4 | $122,000 | $153,000 | *Notes: Thresholds may be lower (e.g., 400% FPL) or flexible. Assets, expenses, and insurance status factor in. Verify with Melinta[3].* ## Insurance Requirements Melinta PAPs generally require **no government insurance** (Medicare Part D, Medicaid, VA, etc.), as federal rules prohibit free drug replacement[3]. Commercial insurance patients may qualify if they face high copays/deductibles or denials. Provide proof of income, denial letters, and insurance details. Medicare patients might access via Extra Help or manufacturer copay cards if available—check specifics[6][10]. ## Step-by-Step Application Process 1. **Consult Your Doctor**: Confirm VABOMERE® is medically necessary. Get a signed prescription. 2. **Gather Documents**: Proof of income (tax returns, pay stubs, SSI/SSDI letters), residency (ID/utility bill), insurance status (card/denial letter), and prescription[3]. 3. **Contact Melinta**: Call **1-844-633-6568** (from labeling) or visit www.melinta.com for PAP forms. Request a VABOMERE® application—similar to Kimyrsa® hub[2][7][9]. RxAssist.org lists Melinta programs[3]. 4. **Submit Application**: Doctor/patient mails/faxes completed form with documents. 5. **Follow Up**: Track status via phone. ## Timeline and Delivery Processing takes **2-4 weeks** typically for PAPs; urgent cases may expedite. Approved medication ships free to your doctor's office or pharmacy for IV prep—hospital coordination often needed[3]. Expect **1-year supply** initially, with reauthorization[3]. ## Alternatives if Denied - **Appeal**: Provide more docs or updated income. - **Other PAPs**: NeedyMeds.org, RxAssist.org, or PAN Foundation. - **Generic meropenem** (if susceptible; vaborbactam is novel). - **Patient Access Network (PAN)** or HealthWell Foundation for copays. - **340B hospitals** or state programs. - **Manufacturer rep**: Request via vabomere.com[1]. ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Eligibility, terms change—contact Melinta directly (1-844-633-6568, www.melinta.com). Consult your healthcare provider. Data based on public sources as of 2026; program may evolve[1][2][3][4][5][9]. (Word count: 1028)

Program information last verified: March 30, 2026